Interim results from the VICTORI study, presented at the ongoing American Association for Cancer Research (AACR) Annual Meeting 2025 (April 25–30), show that an ultrasensitive liquid biopsy assay based on circulating tumor DNA (ctDNA) can detect signs of recurrence. Developed by Personalis, Inc. in collaboration with BC Cancer, the assay can detect molecular residual disease … Study Shows ctDNA Liquid Biopsy Detects Colorectal Cancer Recurrence Earlier Than Imaging Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.